Filing Flows › Biolargo (BLGO) › Q1 2026 › vs Q1 2025
Biolargo (BLGO) Q1 2026 vs Q1 2025 (year over year)
Biolargo's revenue fell $2.2M (-66%) from $3.3M in Q1 2025 to $1.1M in Q1 2026. The biggest changes: Product −$2.2M (-79%); Service +$72K (+15%).
Biolargo, Q1 2026: revenue $1.1M (-66% year over year), operating margin -287.4%, net loss $3.4M, operating cash flow −$2.9M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Product | $577K | $2.8M | −$2.2M | -79% |
| Service | $538K | $466K | $72K | +15% |
| Revenue | $1.1M | $3.3M | −$2.2M | -66% |
| Net loss | $3.4M | $1.9M | $1.5M | +77% |
| Costs & expenses | $4.5M | $5.2M | −$670K | -13% |
| Operating costs | $4.3M | $5.1M | −$812K | -16% |
| Interest & other, net | $201K | $59K | $142K | +241% |
| Cost of revenue | $657K | $1.8M | −$1.1M | -63% |
| Research & development | $907K | $791K | $116K | +15% |
| SG&A | $2.8M | $2.5M | $233K | +9% |
| Operating cash sources | $3.6M | $2.5M | $1.2M | +47% |
| Depreciation | $34K | $42K | −$8K | -19% |
| Share-based compensation | $699K | $615K | $84K | +14% |
| Cash used in operations | $2.9M | $1.8M | $1.1M | +59% |
| Net loss absorbed | $3.4M | $1.9M | $1.5M | +77% |
| Working capital & other | $245K | $566K | −$321K | -57% |
Questions
How much did Biolargo's revenue grow year over year in Q1 2026?
Biolargo's revenue fell $2.2M (-66%) from $3.3M in Q1 2025 to $1.1M in Q1 2026.
What drove Biolargo's revenue change in Q1 2026?
Product −$2.2M (-79%); Service +$72K (+15%).